{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:37:46Z","timestamp":1793072266880,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02678-5","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:02:19Z","timestamp":1774512139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure"],"prefix":"10.1038","volume":"11","author":[{"given":"Wei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-518X","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfeng","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-8396","authenticated-orcid":false,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0087-2277","authenticated-orcid":false,"given":"Zhiying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangtian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1272-3295","authenticated-orcid":false,"given":"Yi Eve","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2678_CR1","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh, T. A. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 44, 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"key":"2678_CR2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/ejhf.3028","volume":"25","author":"PM Burger","year":"2023","unstructured":"Burger, P. M. et al. Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF model. Eur. J. Heart Fail 25, 1962\u20131975 (2023).","journal-title":"Eur. J. Heart Fail"},{"key":"2678_CR3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cvr\/cvab135","volume":"118","author":"R Bolli","year":"2022","unstructured":"Bolli, R., Solankhi, M., Tang, X. L. & Kahlon, A. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovasc Res. 118, 951\u2013976 (2022).","journal-title":"Cardiovasc Res."},{"key":"2678_CR4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2022.11.061","volume":"81","author":"EC Perin","year":"2023","unstructured":"Perin, E. C. et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure. J. Am. Coll. Cardiol. 81, 849\u2013863 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2678_CR5","doi-asserted-by":"crossref","first-page":"166806","DOI":"10.1016\/j.bbadis.2023.166806","volume":"1869","author":"N Sareen","year":"2023","unstructured":"Sareen, N., Srivastava, A., Alagarsamy, K. N., Lionetti, V. & Dhingra, S. Stem cells derived exosomes and biomaterials to modulate autophagy and mend broken hearts. Biochim Biophys. Acta Mol. Basis Dis. 1869, 166806 (2023).","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"2678_CR6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2174\/1566523221666210917114353","volume":"21","author":"C Ulpiano","year":"2021","unstructured":"Ulpiano, C., da Silva, C. L. & Monteiro, G. A. Mesenchymal stromal cells (MSCs): A promising tool for cell-based angiogenic therapy. Curr. Gene Ther. 21, 382\u2013405 (2021).","journal-title":"Curr. Gene Ther."},{"key":"2678_CR7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1161\/CIRCULATIONAHA.105.575118","volume":"113","author":"GP Meyer","year":"2006","unstructured":"Meyer, G. P. et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months\u2019 follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113, 1287\u20131294 (2006).","journal-title":"Circulation"},{"key":"2678_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCRESAHA.116.308937","volume":"119","author":"Y Tokita","year":"2016","unstructured":"Tokita, Y. et al. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ. Res. 119, 635\u2013651 (2016).","journal-title":"Circ. Res."},{"key":"2678_CR9","first-page":"I150","volume":"112","author":"D Hou","year":"2005","unstructured":"Hou, D. et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials. Circulation 112, I150\u2013I156 (2005).","journal-title":"Circulation"},{"key":"2678_CR10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","volume":"121","author":"J Bartolucci","year":"2017","unstructured":"Bartolucci, J. et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1\/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ. Res 121, 1192\u20131204 (2017).","journal-title":"Circ. Res"},{"key":"2678_CR11","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","volume":"143","author":"DJ Weiss","year":"2013","unstructured":"Weiss, D. J., Casaburi, R., Flannery, R., LeRoux-Williams, M. & Tashkin, D. P. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 143, 1590\u20131598 (2013).","journal-title":"Chest"},{"key":"2678_CR12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/stmcls\/sxad087","volume":"42","author":"B Yang","year":"2024","unstructured":"Yang, B. et al. Procoagulant properties of mesenchymal stem cells and extracellular vesicles: a novel aspect of thrombosis pathogenesis. Stem Cells 42, 98\u2013106 (2024).","journal-title":"Stem Cells"},{"key":"2678_CR13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13287-023-03582-3","volume":"15","author":"VT Hoang","year":"2024","unstructured":"Hoang, V. T. et al. Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem\/stromal cell infusions: Re-evaluating the dogma. Stem Cell Res. Ther. 15, 56 (2024).","journal-title":"Stem Cell Res. Ther."},{"key":"2678_CR14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","volume":"25","author":"G Moll","year":"2019","unstructured":"Moll, G. et al. Intravascular mesenchymal stromal\/stem cell therapy product diversification: Time for new clinical guidelines. Trends Mol. Med. 25, 149\u2013163 (2019).","journal-title":"Trends Mol. Med."},{"key":"2678_CR15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7150\/thno.16911","volume":"7","author":"L Liao","year":"2017","unstructured":"Liao, L. et al. Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics 7, 106\u2013116 (2017).","journal-title":"Theranostics"},{"key":"2678_CR16","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. Eradication of specific donor-dependent variations of mesenchymal stem cells in immunomodulation to enhance therapeutic values. Cell Death Dis. 12, 357 (2021).","journal-title":"Cell Death Dis."},{"key":"2678_CR17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.kint.2017.12.010","volume":"93","author":"KN Sivanathan","year":"2018","unstructured":"Sivanathan, K. N. & Coates, P. T. IL-17A-induced mesenchymal stem cells have promising therapeutic value for clinical translation. Kidney Int. 93, 771\u2013773 (2018).","journal-title":"Kidney Int"},{"key":"2678_CR18","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","volume":"16","author":"D Wang","year":"2014","unstructured":"Wang, D. et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: A multicenter clinical study. Arthritis Res. Ther. 16, R79 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"2678_CR19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang, J. et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis. 69, 1423\u20131429 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"2678_CR20","doi-asserted-by":"crossref","first-page":"107491","DOI":"10.1016\/j.vph.2025.107491","volume":"159","author":"A Guan","year":"2025","unstructured":"Guan, A. et al. Clinical translation of mesenchymal stem cells in ischemic heart failure: Challenges and future perspectives. Vasc. Pharm. 159, 107491 (2025).","journal-title":"Vasc. Pharm."},{"key":"2678_CR21","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","volume":"36","author":"AB Mathiasen","year":"2015","unstructured":"Mathiasen, A. B. et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial (MSC-HF trial). Eur. Heart J. 36, 1744\u20131753 (2015).","journal-title":"Eur. Heart J."},{"key":"2678_CR22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1574888X15999200820171432","volume":"16","author":"T Shen","year":"2021","unstructured":"Shen, T. et al. A systematic review and meta-analysis: Safety and efficacy of mesenchymal stem cells therapy for heart failure. Curr. Stem Cell Res Ther. 16, 354\u2013365 (2021).","journal-title":"Curr. Stem Cell Res Ther."},{"key":"2678_CR23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.reth.2025.09.009","volume":"30","author":"TT Tran","year":"2025","unstructured":"Tran, T. T. et al. A comprehensive review of clinical trials and Progress in stem cell therapies for advanced heart failure. Regen. Ther. 30, 812\u2013837 (2025).","journal-title":"Regen. Ther."},{"key":"2678_CR24","first-page":"e49645","volume":"15","author":"MR Abouzid","year":"2023","unstructured":"Abouzid, M. R. et al. The safety and efficacy of human umbilical cord-derived mesenchymal stem cells in patients with heart failure and myocardial infarction: A meta-analysis of clinical trials. Cureus 15, e49645 (2023).","journal-title":"Cureus"},{"key":"2678_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40256-025-00770-9","volume":"26","author":"A D\u2019Amato","year":"2026","unstructured":"D\u2019Amato, A. et al. Early SGLT2i therapy facilitates in-hospital ARNI Introduction improving 6-month systolic function in patients with HFrEF. Am. J. Cardiovasc Drugs 26, 205\u2013214 (2026).","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"2678_CR26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi, J. L. Jr et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322, 1085\u20131095 (2019).","journal-title":"JAMA"},{"key":"2678_CR27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","volume":"69","author":"JM Hare","year":"2017","unstructured":"Hare, J. M. et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J. Am. Coll. Cardiol. 69, 526\u2013537 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2678_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","volume":"311","author":"AW Heldman","year":"2014","unstructured":"Heldman, A. W. et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. Jama 311, 62\u201373 (2014).","journal-title":"Jama"},{"key":"2678_CR29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCRESAHA.116.309717","volume":"120","author":"J Butler","year":"2017","unstructured":"Butler, J. et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: Safety and efficacy results of a phase II-A randomized trial. Circ. Res. 120, 332\u2013340 (2017).","journal-title":"Circ. Res."},{"key":"2678_CR30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ejhf.2772","volume":"25","author":"AA Qayyum","year":"2023","unstructured":"Qayyum, A. A. et al. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial. Eur. J. Heart Fail 25, 576\u2013587 (2023).","journal-title":"Eur. J. Heart Fail"},{"key":"2678_CR31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14779072.2017.1379898","volume":"15","author":"MS Si","year":"2017","unstructured":"Si, M. S. & Ohye, R. G. Stem cell therapy for the systemic right ventricle. Expert Rev. Cardiovasc Ther. 15, 813\u2013823 (2017).","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"2678_CR32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13287-024-04009-3","volume":"15","author":"N Makkaoui","year":"2024","unstructured":"Makkaoui, N. et al. Cell-based therapies reverse the heart failure-altered right ventricular proteome towards a pre-disease state. Stem Cell Res. Ther. 15, 420 (2024).","journal-title":"Stem Cell Res. Ther."},{"key":"2678_CR33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13287-023-03354-z","volume":"14","author":"X Li","year":"2023","unstructured":"Li, X. et al. Intravenous injection of human umbilical cord-derived mesenchymal stem cells ameliorates not only blood glucose but also nephrotic complication of diabetic rats through autophagy-mediated anti-senescent mechanism. Stem Cell Res. Ther. 14, 146 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"2678_CR34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jchf.2022.04.015","volume":"10","author":"PW Armstrong","year":"2022","unstructured":"Armstrong, P. W. et al. Sequential evaluation of NT-proBNP in heart failure: insights into clinical outcomes and efficacy of vericiguat. JACC Heart Fail 10, 677\u2013688 (2022).","journal-title":"JACC Heart Fail"},{"key":"2678_CR35","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s10741-022-10258-2","volume":"27","author":"S Savarimuthu","year":"2022","unstructured":"Savarimuthu, S., Goel, P. & Harky, A. Soluble ST2: A valuable prognostic marker in heart failure. Heart Fail Rev. 27, 2155\u20132164 (2022).","journal-title":"Heart Fail Rev."},{"key":"2678_CR36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41392-024-01936-8","volume":"9","author":"Y Shan","year":"2024","unstructured":"Shan, Y. et al. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges. Signal Transduct. Target Ther. 9, 242 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2678_CR37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/cvr\/cvae173","volume":"120","author":"XL Tang","year":"2024","unstructured":"Tang, X. L. et al. Intravenous infusions of mesenchymal stromal cells have cumulative beneficial effects in a porcine model of chronic ischaemic cardiomyopathy. Cardiovasc Res. 120, 1939\u20131952 (2024).","journal-title":"Cardiovasc Res."},{"key":"2678_CR38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s13287-022-03101-w","volume":"13","author":"C Gong","year":"2022","unstructured":"Gong, C. et al. Infusion of two-dose mesenchymal stem cells is more effective than a single dose in a dilated cardiomyopathy rat model by upregulating indoleamine 2,3-dioxygenase expression. Stem Cell Res. Ther. 13, 409 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"2678_CR39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/eurjhf\/hfp062","volume":"11","author":"K Yao","year":"2009","unstructured":"Yao, K. et al. Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction. Eur. J. Heart Fail 11, 691\u2013698 (2009).","journal-title":"Eur. J. Heart Fail"},{"key":"2678_CR40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1253\/circj.CJ-10-0898","volume":"75","author":"X Gu","year":"2011","unstructured":"Gu, X. et al. Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure-a pilot study. Circ. J. 75, 955\u2013963 (2011).","journal-title":"Circ. J."},{"key":"2678_CR41","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, e263\u2013e421 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2678_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/IJHR.IJHR_5_23","volume":"9","author":"J Jiang","year":"2024","unstructured":"Jiang, J. & Zhang, S. Current status and challenges of interventional therapy for diagnosis and treatment of arrhythmia in China. Int. J. Heart Rhythm 9, 1\u20136 (2024).","journal-title":"Int. J. Heart Rhythm"},{"key":"2678_CR43","doi-asserted-by":"crossref","first-page":"101350","DOI":"10.1016\/j.conctc.2024.101350","volume":"41","author":"X Gong","year":"2024","unstructured":"Gong, X. et al. A prospective randomized controlled study of multi-intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure and reduced ejection fraction (PRIME-HFrEF) trial: Rationale and design. Contemp. Clin. Trials Commun. 41, 101350 (2024).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"2678_CR44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1148\/radiol.10090526","volume":"258","author":"CJ Harrigan","year":"2011","unstructured":"Harrigan, C. J. et al. Hypertrophic cardiomyopathy: Quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 258, 128\u2013133 (2011).","journal-title":"Radiology"},{"key":"2678_CR45","first-page":"1431","volume":"45","author":"JA Thie","year":"2004","unstructured":"Thie, J. A. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med. 45, 1431\u20131434 (2004).","journal-title":"J. Nucl. Med"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02678-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02678-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02678-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:29:47Z","timestamp":1774513787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02678-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2678"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02678-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}